Skip to content
Screener

Beam Therapeutics BEAM Total Liabilities

Total Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$7.12B+11.6%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.55B+34.8%
MGN
MagniteMGNI
$2.1B-2.9%
Wave Life Sciences logo
Wave Life SciencesWVE
$104.8M-0.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$129.46M-29.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$911.26M+170%

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$2.81B+52.0%
Enterprise value$2.78B+61.1%
P/S17.2×-13.6×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:22 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210338
Line itemMarch 31,2026December 31,2025
Long-term portion of contingent consideration liabilities5,4495,952
Long-term portion of debt100,193
Other liabilities305173
Total liabilities316,360242,819
Commitments and contingencies (See Note 7, License and other agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 102,741,848 and 101,748,962 issued and outstanding at March 31, 2026 and December 31, 2025, respectively1,0271,017

Item 1. Financial Statements (Unaudited)

FAQ

What is Beam Therapeutics's total liabilities?
Beam Therapeutics (BEAM) reported total liabilities of $316.36M in Q1 2026.
How has Beam Therapeutics's total liabilities changed year-over-year?
Beam Therapeutics's total liabilities decreased by 8.0% year-over-year, from $343.78M to $316.36M.
What is the long-term trend for Beam Therapeutics's total liabilities?
Over 5 years (2020 to 2025), Beam Therapeutics's total liabilities has grown at a 3.3% compound annual growth rate (CAGR), from $206.12M to $242.82M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Beam Therapeutics's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude